These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

563 related items for PubMed ID: 29255294

  • 1. PAX7 target genes are globally repressed in facioscapulohumeral muscular dystrophy skeletal muscle.
    Banerji CRS, Panamarova M, Hebaishi H, White RB, Relaix F, Severini S, Zammit PS.
    Nat Commun; 2017 Dec 18; 8(1):2152. PubMed ID: 29255294
    [Abstract] [Full Text] [Related]

  • 2. PAX7 target gene repression is a superior FSHD biomarker than DUX4 target gene activation, associating with pathological severity and identifying FSHD at the single-cell level.
    Banerji CRS, Zammit PS.
    Hum Mol Genet; 2019 Jul 01; 28(13):2224-2236. PubMed ID: 31067297
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Expression patterns of FSHD-causing DUX4 and myogenic transcription factors PAX3 and PAX7 are spatially distinct in differentiating human stem cell cultures.
    Haynes P, Kernan K, Zhou SL, Miller DG.
    Skelet Muscle; 2017 Jun 21; 7(1):13. PubMed ID: 28637492
    [Abstract] [Full Text] [Related]

  • 5. Pathomechanisms and biomarkers in facioscapulohumeral muscular dystrophy: roles of DUX4 and PAX7.
    Banerji CRS, Zammit PS.
    EMBO Mol Med; 2021 Aug 09; 13(8):e13695. PubMed ID: 34151531
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Single-cell RNA sequencing in facioscapulohumeral muscular dystrophy disease etiology and development.
    van den Heuvel A, Mahfouz A, Kloet SL, Balog J, van Engelen BGM, Tawil R, Tapscott SJ, van der Maarel SM.
    Hum Mol Genet; 2019 Apr 01; 28(7):1064-1075. PubMed ID: 30445587
    [Abstract] [Full Text] [Related]

  • 8. Facioscapulohumeral dystrophy transcriptome signatures correlate with different stages of disease and are marked by different MRI biomarkers.
    van den Heuvel A, Lassche S, Mul K, Greco A, San León Granado D, Heerschap A, Küsters B, Tapscott SJ, Voermans NC, van Engelen BGM, van der Maarel SM.
    Sci Rep; 2022 Jan 26; 12(1):1426. PubMed ID: 35082321
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. DUX4-induced constitutive DNA damage and oxidative stress contribute to aberrant differentiation of myoblasts from FSHD patients.
    Dmitriev P, Bou Saada Y, Dib C, Ansseau E, Barat A, Hamade A, Dessen P, Robert T, Lazar V, Louzada RAN, Dupuy C, Zakharova V, Carnac G, Lipinski M, Vassetzky YS.
    Free Radic Biol Med; 2016 Oct 26; 99():244-258. PubMed ID: 27519269
    [Abstract] [Full Text] [Related]

  • 11. β-Catenin is central to DUX4-driven network rewiring in facioscapulohumeral muscular dystrophy.
    Banerji CR, Knopp P, Moyle LA, Severini S, Orrell RW, Teschendorff AE, Zammit PS.
    J R Soc Interface; 2015 Jan 06; 12(102):20140797. PubMed ID: 25551153
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. DUX4 expressing immortalized FSHD lymphoblastoid cells express genes elevated in FSHD muscle biopsies, correlating with the early stages of inflammation.
    Banerji CRS, Panamarova M, Zammit PS.
    Hum Mol Genet; 2020 Aug 11; 29(14):2285-2299. PubMed ID: 32242220
    [Abstract] [Full Text] [Related]

  • 15. Facioscapulohumeral dystrophy: incomplete suppression of a retrotransposed gene.
    Snider L, Geng LN, Lemmers RJ, Kyba M, Ware CB, Nelson AM, Tawil R, Filippova GN, van der Maarel SM, Tapscott SJ, Miller DG.
    PLoS Genet; 2010 Oct 28; 6(10):e1001181. PubMed ID: 21060811
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Gene expression during normal and FSHD myogenesis.
    Tsumagari K, Chang SC, Lacey M, Baribault C, Chittur SV, Sowden J, Tawil R, Crawford GE, Ehrlich M.
    BMC Med Genomics; 2011 Sep 27; 4():67. PubMed ID: 21951698
    [Abstract] [Full Text] [Related]

  • 18. Model systems of DUX4 expression recapitulate the transcriptional profile of FSHD cells.
    Jagannathan S, Shadle SC, Resnick R, Snider L, Tawil RN, van der Maarel SM, Bradley RK, Tapscott SJ.
    Hum Mol Genet; 2016 Oct 15; 25(20):4419-4431. PubMed ID: 28171552
    [Abstract] [Full Text] [Related]

  • 19. An isogenetic myoblast expression screen identifies DUX4-mediated FSHD-associated molecular pathologies.
    Bosnakovski D, Xu Z, Gang EJ, Galindo CL, Liu M, Simsek T, Garner HR, Agha-Mohammadi S, Tassin A, Coppée F, Belayew A, Perlingeiro RR, Kyba M.
    EMBO J; 2008 Oct 22; 27(20):2766-79. PubMed ID: 18833193
    [Abstract] [Full Text] [Related]

  • 20. MRI-informed muscle biopsies correlate MRI with pathology and DUX4 target gene expression in FSHD.
    Wang LH, Friedman SD, Shaw D, Snider L, Wong CJ, Budech CB, Poliachik SL, Gove NE, Lewis LM, Campbell AE, Lemmers RJFL, Maarel SM, Tapscott SJ, Tawil RN.
    Hum Mol Genet; 2019 Feb 01; 28(3):476-486. PubMed ID: 30312408
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.